NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables dips below year-ago levels
Q1 FY2026 accounts payables of $129K fell 27.5% year over year, behind the +100.9% change in trailing-twelve-month accounts payables. Sequentially, it rose 892.3% from the prior quarter.
Context
- Accounts payables amounted to 9.2% of revenue in FY2025.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -27.5% toward the trailing-twelve-month pace of +100.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 113K USD
- Year-over-year change
- +102.2%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 113K | +102.2% |
| FY2024 | 2024-12-31 | (5.22M) | -296.5% |
| FY2023 | 2023-12-31 | 2.66M | +264.8% |
| FY2022 | 2022-12-31 | (1.61M) | -8378.9% |
| FY2021 | 2021-12-31 | (19K) | — |
Accounts Payables vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's LTM Mar 2026 accounts payables of $64K is the smallest of the 9 companies compared; the peer median is $441K.
- Its year-over-year change of +100.9% is the 3rd highest of 9, against a peer median of -23.3%.
- Accounts payables amounts to 2.8% of revenue for NRXP, versus a peer median of 7.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.9M | +28.5% | +8.8% | 1472.1% | |
| LTM Jun 2026 | $3.45M | -438.7% | +104.0% | 16.4% | |
| LTM Mar 2026 | $1.88M | -646.1% | — | — | |
| LTM Mar 2026 | $1.59M | +8.7% | — | 1.1% | |
| LTM Mar 2026 | $764K | +6466.7% | -36.8% | — | |
| LTM Mar 2026 | $458K | +239.3% | +138.4% | 1.4% | |
| LTM Mar 2026 | $424K | -76.4% | — | — | |
| LTM Mar 2026 | $109.49K | -55.4% | +121.5% | 7.7% | |
| LTM Mar 2026 | $64K | +100.9% | — | 2.8% | |
| Peer median (excluding NRXP) | $441K | -23.3% | +104.0% | 7.7% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (93.06M) | (39.75M) | (30.15M) | (25.13M) | (28.62M) |
| Depreciation & Amortization | 2K | 4K | 5K | 5K | 143K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 7.79M | 3.63M | 387K | 486K | 228K |
| Change in Working Capital | (4.9M) | 699K | 5.16M | 5.29M | 1.41M |
| Accounts Receivables | 831K | 0 | 0 | 0 | 48K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (19K) | (1.61M) | 2.66M | (5.22M) | 113K |
| Other Working Capital | (5.71M) | 2.31M | 2.51M | 10.51M | 1.25M |
| Other Non-Cash Items | 52.47M | (4.33M) | 2.94M | 8.71M | 12.73M |
| Operating Cash Flow | (37.7M) | (39.76M) | (21.66M) | (10.64M) | (14.11M) |
| Capital Expenditures | (7K) | (10K) | (3K) | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | (2.38M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | (432K) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (7K) | (10K) | (3K) | 0 | (2.81M) |
| Debt Repayment | (1.28M) | 9.5M | (3.09M) | (1.5M) | 7.42M |
| Common Stock Issued | 36.98M | 22.7M | 8.12M | 5.91M | 15.86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 27.75M | 10K | 0 | 3.07M | 0 |
| Financing Cash Flow | 63.46M | 32.21M | 6.2M | 7.49M | 23.28M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 25.75M | (7.55M) | (15.46M) | (3.15M) | 6.35M |
| Free Cash Flow | (37.71M) | (39.77M) | (21.66M) | (10.64M) | (14.11M) |
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.